Evidence map›Paper›PMID 36595042›Full record

Trial reportJournal of cancer research and clinical oncology2023

Bevacizumab biosimilar candidate TAB008 compared to Avastin

S Lu, S Qin, Z Zhou, J Chen, K Gu, P Sun, Y Pan, G Yu, K Ma, J Shi and 5 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05427305 (Bevacizumab Biosimilar Candidate TAB008 Compared to Avastin® in Patients With Locally Advanced, Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer), which is not on this map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05427305 phase3completednot on this map

Bevacizumab Biosimilar Candidate TAB008 Compared to Avastin® in Patients With Locally Advanced, Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Multicenter Study

TypeinterventionalSponsorBioDlink Biopharm Co., Ltd.Ran2017 to 2020Enrolled549ConditionsEfficacyArmsTAB008, Bevacizumab
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Biosimilar monoclonal antibodies for cancer treatment in adults.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

S LuLung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
S QinCancer Center, Nanjing Jinling Hospital, Nanjing, China. qinsk@csco.org.cn.
Z ZhouLung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
J ChenOncology, Hunan Cancer Hospital, Changsha, China.
K GuOncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
P SunOncology, Yantai Yuhuangding Hospital, Yantai, China.
Y PanOncology, Anhui Provincial Hospital, Hefei, China.
G YuOncology, Weifang People's Hospital, Weifang, China.
K MaOncology, Jilin University First Hospital, Jilin, China.
J ShiOncology, Linyi Cancer Hospital, Linyi, China.
Y SunOncology, Jinan Central Hospital, Jinan, China.
L YangCancer Center, Nanjing Jinling Hospital, Nanjing, China.
P ChenOncology, Yancheng First People's Hospital, Yancheng, China.
A LiuOncology, Nanchang University Second Affiliated Hospital, Nanchang, China.
J HeStatistics, The Second Military Medical University, Shanghai, China.
Nanjing General Hospital of Nanjing Military Command · CNShanghai Chest Hospital · CNAnhui Provincial Hospital · CNFirst Affiliated Hospital of Anhui Medical University · CNHunan Cancer Hospital · CNJilin University · CNJinan Central Hospital · CNNantong University · CNSecond Affiliated Hospital of Nanchang University · CNSecond Military Medical University · CNWeifang People's Hospital · CNYuhuangding Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBevacizumab (Avastin

methodIn this randomized, double-blind, multicenter, phase III similarity study, treatment naïve for metastatic lung cancer., EGFR wild-type, locally advanced, metastatic, or recurrent non-squamous, non-small cell, lung cancer (nsNSCLC) patients were enrolled and randomized (1:1) into TAB008 or Avastin

resultsA total of 549 nsNSCLC patients were enrolled (277 in TAB008 group and 272 in Avastin

conclusionsTAB008 is similar to Avastin

trial registrationClinicalTrials.gov number; NCT05427305.

Indexed as

Biosimilar PharmaceuticalsCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDouble-Blind MethodErbB ReceptorsHumansPaclitaxelVascular Endothelial Growth Factor ABevacizumabBiosimilar PharmaceuticalsEGFR protein, humanErbB ReceptorsPaclitaxelVascular Endothelial Growth Factor AAvastin® biosimilarEGFR wild-typeNon squamous non-small cell lung cancer (nsNSCLC)TAB008

Identifiers

PMID36595042
PMCPMC11796671
OpenAlexW4313453457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.